|
Current issue
Archive
Online First
About the journal
Editorial board
Abstracting and indexing
Subscription
Contact
Ethical standards and procedures
Special Issues
Instructions for authors
Publication charge
Editorial System
Submit your Manuscript
Open access 
|
1/2010
vol. 9 abstract:
Review paper
17ß-oestradiol (1 mg) plus drospirenone (2 mg) in hormonal therapy of postmenopausal period
Grzegorz Stachowiak
,
Tomasz Pertyński
Przegląd Menopauzalny 2010; 1: 1–4
Online publish date: 2010/02/25
View
full text
Get citation
ENW EndNote
BIB JabRef, Mendeley
RIS Papers, Reference Manager, RefWorks, Zotero
AMA
APA
Chicago
Harvard
MLA
Vancouver
Low-dose oral MHT combining 1 mg oestradiol (E2) and 2 mg drospirenone (DRSP) is effective in alleviating climacteric and urogenital symptoms, prevents endometrial hyperplasia, reduces the risk of osteoporosis, and has a positive influence on lipid profile, carbohydrate metabolism, arterial pressure and female quality of life. This safe type of MHT can be a drug of first choice for the big group of women after menopause.
keywords:
menopause, drospirenone, oestradiol, oral hormonal therapy, progestogens |
 |
